| [1] Prensner JR, Chinnaiyan AM. Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev, 2009, 19(1): 82–91. [2] Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer, 2008, 8(7): 497–511. [3] Narod SA, Seth A, Nam R. Fusion in the ETS gene family and prostate cancer. Br J Cancer, 2008, 99(6): 847–851. [4] 郭晓强. 跨膜丝氨酸蛋白酶研究进展. 生理科学进展, 2009, 40(2): 182–184. [5] Paoloni-Giacobino A,Chen HM, Peitsch MC, Rossier C, Antonarakis SE. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics, 1997, 44(3): 309–320. [6] Vaarala MH, Porvari KS, Kellokumpu S, Kyllönen AP, Vihko PT. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J Pathol, 2001, 193(1): 134–140. [7] Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L, Nelson PS. Prostate-localized and andro-gen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res, 1999, 59(17): 4180–4184. [8] Vaarala MH, Porvari K, Kyllönen A, Lukkarinen O, Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer, 2001, 94(5): 705–710. [9] Afar DE, Vivanco I, Hubert RS, Kuo J, Chen E, Saffran DC, Raitano AB, Jakobovits A. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its se-cretion by prostate and prostate cancer epithelia. Cancer Res, 2001, 61(4): 1686–1692. [10] Gutierrez-Hartmann A, Duval DL, Bradford AP. ETS transcription factors in endocrine systems. Trends Endo-crinol Metab, 2007, 18(4): 150–158. [11] De Val S, Black BL. Transcriptional control of endothelial cell development. Dev Cell, 2009, 16(2): 180–195. [12] Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao XH, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 2005, 310(5748): 644–648. [13] Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao XH, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res, 2006, 66(7): 3396–3400. [14] Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, Eeles R, Martin FL, Phillips DH, Crundwell M, Christmas T, Thompson A, Fisher C, Kovacs G, Cooper CS. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene, 2007, 26(18): 2667–2673. [15] Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2- ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep, 2007, 17(5): 1033–1036. [16] Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol, 2007, 20(9): 921–928. [17] Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol, 2007, 20(5): 538–544. [18] Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. Cancer Res, 2009, 69(2): 640–646. [19] Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA. Preva |
